⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Flow Cytometry Market Poised for Growth Through 2029 as Technology Advances, Product Innovation and Expanding Applications Create New Opportunities
globenewswire.com
BIIB
BDX
BIO
CYTK
TMO
Global Lupus Nephritis Market to Reach USD 4.08 Billion by 2034 at 8.5% CAGR as Rising Disease Burden and Breakthroughs in Targeted Therapies Accelerate Market Expansion, Says Maximize Market Research
prnewswire.com
PFE
AZN
MRK
BMY
GSK
AMGN
BIIB
JNJ
VRTX
IMVT
ABBV
LLY
SNY
REGN
GILD
BHC
AUR
UCB
Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight
globenewswire.com
ABT
BIO
AMGN
BMY
AXSM
JNJ
LLY
NVO
QTRX
DGX
TMO
QRVO
GILD
REGN
BIIB
ALKS
ACAD
PTGX
CRIS
EXAS
TDOC
QRHC
AMZN
GOOG
MSFT
IBM
NVDA
INTC
AMD
QCOM
AMAT
LRCX
KLAC
MU
ADI
NXPI
TXN
MRVL
ON
CDNS
SNPS
MCHP
AEHR
ENPH
PLUG
FCEL
PLTR
AI
CRBU
EDIT
BEAM
NTLA
BNTX
MRNA
PFE
JAZZ
ACGL
ZBRA
MSCI
ROST
SWKS
MDT
TNDM
XRAY
ALGN
IDXX
EXPE
CTAS
ILMN
DXCM
ASML
ADBE
PEGylated Proteins Market - Global Forecast 2026-2032
globenewswire.com
TMO
NVO
MRK
PFE
TAK
BIIB
BMRN
VTRS
First patient treated with Leqembi® (lecanemab) in Sweden
prnewswire.com
BIIB
Fingerpaint Group Appoints Wyatt Gotbetter as President of Market Access
prnewswire.com
BIIB
BSX
Peer AI Expands Submission Risk Prediction with Live Agency Monitoring
prnewswire.com
BIIB
TAK
BCRX
Envisagenics and Boehringer Ingelheim Enter Multi-Target Collaboration to Develop First-in-Class Precision Therapies Based on RNA Splicing-Derived Targets for Hard-to-Treat Cancers
globenewswire.com
BIIB
Encouraging High-Pressure Slurry Ablation Test Results at Myriad's Copper Mountain Uranium Project Ready to Announce with Confidence?
newsfilecorp.com
UEC
CCJ
NVDA
GOOG
MSFT
AMZN
INTC
AMD
MU
PLTR
XOM
CVX
NRG
NEE
ETR
EXC
EFC
CLPS
IBM
HPQ
DELL
QCOM
AMAT
LRCX
WDC
BIIB
GILD
REGN
VRTX
CRSP
BNTX
MRNA
COIN
PYPL
UPST
ROKU
NFLX
DIS
GOOGL
META
TSLA
Cell Culture Matrices Market Set for Growth Through 2033, Fueled by 3D Cell Culture, Biopharma R&D and Regenerative Medicine Advances
globenewswire.com
COR
TMO
BIIB